Major Depressive Disorder: Improving Patient Outcomes with Shared Decision-Making
This activity is jointly provided by Primary Care Network and PlatformQ Health Education, LLC.
Release date: March 13, 2019
Valid through: March 13, 2020
Estimated Time to Complete Activity: 1 hour
Scroll to the Bottom of this Information to Begin this Course
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Primary Care Network and PlatformQ Health Education, LLC. Primary Care Network is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statements
Live Online Activity
Primary Care Network designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Online On-Demand Enduring Material
Primary Care Network designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. All other healthcare professionals will be issued a certificate of participation.
Primary Care Network has been awarded Accreditation with Commendation (2013-2019) by the Accreditation Council for Continuing Medical Education (ACCME).
Upon completion of this activity, participants should be able to:
- Summarize the principles of SDM and apply them to the management of patients with MDD who are candidates for psychopharmacologic therapies
- Compare and contrast the unique mechanisms of action and clinical characteristics of new and emerging therapies, including clinical trial data and real life experiences, as they apply to SDM and individualized treatment in patients with MDD
- Incorporate SDM principles and knowledge of the clinical characteristics of psychopharmacologic therapies to the management of complex patients with MDD in real life settings, including treatment selection, setting of treatment goals, appropriate monitoring, and optimal management of nonadherence and refractory disease
This program is primarily intended for psychiatrists, psychologists, family physicians, internal medicine physicians, advanced practice providers, nurses, pharmacists, and other HCPs involved in the care of patients with MDD.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Otsuka, Alkermes, Inc., Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
Method of Participation
There are no fees to participate in this activity. To participate in the activity, go to https://www.psychiatrycarelive.com To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the pre and post-test and activity evaluation. Participants must receive a minimum score of 70% on the post-test in order to receive a certificate.
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Statement of Disclosure and Independence
It is the policy of Primary Care Network (PCN) to ensure all of its accredited educational activities are planned, developed, and conducted in accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Essential Areas and Policies. In accordance with ACCME requirements, PCN has Conflict of Interest (COI) and Disclosure Policies that are designed to ensure that PCN accredited educational activities are fair, balanced, independent, evidence based, and based on scientific rigor.
PCN’s Resolution of Personal COI Policy aims to ensure that all potential conflicts are identified and resolved prior to the activity, content is developed and presented free of commercial bias, and is in the interest of promoting improvements or quality in healthcare. All individuals who are in a position to influence and/or control content of a PCN accredited Continuing Medical Education (CME) activity are considered Planning Committee Members.
Planning Committee Members include individuals involved in a CME activity who may develop, edit, review and/or present content. Planning Committee Members are required to disclose to the participants any real or apparent conflict(s) of interest related to the activity. The educational content is also reviewed for independence and content validation by an independent clinical reviewer. Independence is also monitored through the activity and overall program evaluation process.
The faculty reported the following relevant financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Name of Faculty or Presenter||Reported Relevant Financial Relationship|
|Michael E. Thase, MD||Consultant: Allergan, Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Otsuka Pharmaceutical, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Acadia, Inc., Akili, Inc., Alkermes PLC, Cerecor, Inc., Fabre-Kramer Pharmaceuticals, Inc., Gerson Lehrman Group-, Inc., Guidepoint Global, LLC, Johnson & Johnson, H. Lundbeck, A/S, Moksha8 Pharmaceuticals, Inc., Nestle (PamLab), Neuralstrim, Sage Pharmaceuticals, Agency for Healthcare Research and Quality, AssureRx Health, Inc., Avanir, Axome, Inc. |
Research/Grants: Allergan, Inc., Janssen Pharmaceuticals, Inc., Pfizer, Inc., Takeda Pharmaceuticals, Acadia, Inc., Alkermes PLC, Johnson & Johnson, Intracellular, Inc., National Institutes of Health, Patient-Centered Outcomes Research Institute
Research/Grants: American Psychiatric Foundation, Guilford Publication, Herald House, W.W. Norton & Company, Inc.
Spouse: Peleton Advantage
|Larry Culpepper, MD, MPH||Advisory Board: Eisai Inc., Merck & Co., Purdue Pharma, Shire, Alkermes Inc., Harmony Biosciences LLC, Jazz Pharmaceuticals, Sunovion Pharmaceuticals Inc., Supernus Pharmaceuticals |
Advisory BoardConsultant: Merck & Co., Alkermes Inc.
|Name of Planner||Reported Relevant Financial Relationship|
|Curtis P. Schreiber, MD |
CME Content Reviewer
Primary Care Network
|Advisory Board: Amgen |
Research Grants: Amgen, Genentech, Roche
Speaker's Bureau: Amgen, Novartis
|David Howard |
PlatformQ Health Education, LLC
|Has no relevant financial relationships to disclose|
The following PCN planner and manager, Jill Hays, hereby state that she or her spouse/life partner do not have any relevant financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any relevant financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
The opinions, ideas, recommendations, and perspectives expressed in this activity are those of the program authors and presenting faculty only and do not necessarily reflect the opinions, ideas, recommendations or perspectives of their affiliated institutions, Primary Care Network, advisory boards or consultants.
Please contact Primary Care Network at http://www.primarycarenetwork.org.
For any technical issues or issues with your CME Certificate, please contact PsychiatryCareLive at 877-394-1306 or at https://www.psychiatrycarelive.com.
Information we collect is primarily used to communicate with program participants, award CME/CE credits, manage user accounts, recommend relevant programs and perform data analysis to inform educational outcomes.
In plain English, here is what we affirm:
- You can change your registration profile at any time from our “Profile” page
- To request any of these changes without logging in, please call us at 1 (877) 394-1306 or email us at support@PlatformQHealth.com
- You can end your association with PlatformQ Health at any time
- PlatformQ Health does not spam, nor do we do we rent or sell our email list in whole or in part. Any program-related data sharing is for engagement verification and opt-in based further education
- EU citizens can request a complete record of their account and/or request to have their personal data expunged by contacting email@example.com with the subject line “Data Request”